Pseudomonas aeruginosa is a formidable adversary in hospitals. It thrives in moist environments, infects ventilated patients, and causes ventilator-associated pneumonia, bloodstream infections, catheter-associated urinary tract infections, and surgical site infections, particularly in critically ill or immunocompromised people. Its defenses are layered: the bacterium’s outer membrane is intrinsically impermeable to many drugs, it deploys multidrug efflux pumps that expel antibiotics before they reach their targets, it alters the molecular targets those antibiotics are designed to hit, and it produces β-lactamases, enzymes that chemically dismantle penicillin-class drugs. Together these mechanisms allow the emergence of isolates classified as multidrug-resistant (MDR), extensively drug-resistant (XDR), and difficult-to-treat resistant (DTR) — categories that translate directly into prolonged hospitalization, higher costs, and increased mortality.

The study team, led by Wael A. Alghamdi of King Khalid University together with colleagues at Khamis Mushait General Hospital in the Aseer region, took a deliberately rigorous approach to the data. To avoid inflating resistance rates through repeated sampling of the same patients, the researchers deduplicated isolates at the patient level: for each calendar year, only the first P. aeruginosa isolate per patient was counted, with priority given to the most clinically significant source when several specimens were taken on the same day. Because a single patient could still contribute one isolate in different years, the team ran a sensitivity analysis restricted to 352 patients with no repeated observations, ensuring that temporal trends were not an artifact of non-independent data.

Resistance phenotypes were classified according to established international definitions. MDR isolates were non-susceptible to at least one agent in three or more antimicrobial categories; XDR isolates were non-susceptible to all but one or two categories; and DTR isolates, a clinically grounded classification proposed by Kadri and colleagues, were non-susceptible to all the principal first-line antipseudomonal β-lactams and fluoroquinolones. Bacterial identification and susceptibility testing were performed with the MicroScan automated broth microdilution system throughout the study, with results interpreted against the Clinical and Laboratory Standards Institute breakpoints in force at the time. Overall, 92.5 percent of potential susceptibility results were available, and missing results were left unimputed rather than guessed.

The headline finding is a dramatic arc in resistance prevalence. MDR rose from 51.0 percent of isolates in 2018 to a striking peak of 87.3 percent in 2022, before falling back to 69.6 percent in 2024. XDR climbed from 33.3 percent in 2018 to its highest level of 68.3 percent in 2023, then dropped sharply to 39.1 percent in 2024. DTR, the most clinically restrictive category, stayed lower throughout, ranging from 11.8 percent in 2018 to a peak of 31.7 percent in 2023 before declining to 15.2 percent in 2024. When calendar year was analyzed as a categorical variable, the differences across years were statistically significant for MDR (likelihood-ratio χ² = 33.25, P < 0.001) and XDR (χ² = 20.16, P = 0.003), but not for DTR (χ² = 9.57, P = 0.144).

Crucially, the temporal signal survived statistical scrutiny. In multivariable logistic regression models adjusted for age group, sex, nationality, and specimen source — built on the restricted dataset of 352 unique patients — collection year remained significantly associated with MDR (P < 0.001) and XDR (P = 0.013), but not DTR (P = 0.398). Compared with 2018, the adjusted odds of MDR were roughly six-fold higher in 2022 (adjusted odds ratio 6.12, 95 percent confidence interval 2.25–16.63) and nearly three-fold higher in 2023 (aOR 2.98, 95 percent CI 1.13–7.84), while the adjusted odds of XDR were significantly elevated in 2023 (aOR 3.59, 95 percent CI 1.41–9.11). This means the temporal pattern was not explained simply by shifts in the kinds of patients or specimen types being sampled.

The drug-specific data reveal a subtler story beneath the phenotype curves. Ciprofloxacin non-susceptibility surged from 44.0 percent in 2018 to 97.8 percent in 2024 — a near-total collapse of fluoroquinolone utility against these isolates. In contrast, non-susceptibility to the carbapenems imipenem and meropenem actually declined over the same period, falling from 45.7 percent and 41.2 percent to 30.4 percent and 27.3 percent respectively. This divergence suggests that resistance in P. aeruginosa does not move in one direction uniformly: some drug classes erode steadily while others can recover, presumably reflecting changing prescribing pressures, infection control dynamics, and shifts in circulating strains, though the study’s phenotypic design could not disentangle the mechanisms.

The patient and specimen profile of the cohort adds clinical context. Isolates came more often from male patients (68.5 percent), and nearly half came from people over 60 years of age (49.7 percent), a population with greater healthcare exposure and comorbidity burden. Respiratory tract specimens were the most common source, accounting for 35.1 percent of isolates, followed by urine and genital tract samples (28.3 percent) and wound, pus, and tissue specimens (24.7 percent), with blood and sterile body fluids at 12.0 percent. Interestingly, male sex was associated with higher adjusted odds of all three resistance phenotypes, and specimen source was significantly associated with DTR: isolates from urine and from wounds had markedly lower odds of DTR than bloodstream isolates, a pattern consistent with the severity of infections that reach the bloodstream.

What drove the rise and fall? The authors are appropriately cautious. An antimicrobial stewardship program was introduced at the study institution during the surveillance period, and the decline in MDR and XDR prevalence after 2022 and 2023 may be consistent with such interventions taking hold — but the retrospective, observational design makes it impossible to attribute the downturn to any specific measure. The fluctuations may equally reflect changes in antimicrobial prescribing practices, infection prevention measures, and evolving healthcare utilization, including the massive disruption that the COVID-19 pandemic years imposed on hospitals worldwide. Continuous longitudinal surveillance, the authors argue, is precisely what allows institutions to detect these swings and evaluate stewardship efforts over time.

The study also carries important limitations. It was retrospective and laboratory-based, so detailed clinical information — antimicrobial exposure, comorbidities, treatments, and outcomes — was unavailable, and infection could not be reliably distinguished from colonization for every isolate. No molecular characterization was performed, so the phenotypic trends cannot be pinned on clonal expansion or the spread of specific resistance genes. Annual isolate numbers varied considerably, from as few as 41 in 2023 to 75 in 2021, which makes year-to-year percentages sensitive to small changes. Susceptibility was interpreted using CLSI breakpoints in effect at the time of testing, so revisions during the seven-year window may have introduced some variability in longitudinal classification. Residual confounding by unmeasured clinical factors also remains possible.

Even with those caveats, the numbers land with force. A national multicenter surveillance study from Saudi Arabia recently reported that 25.8 percent of clinical P. aeruginosa isolates in the country’s southern region were DTR and 4.5 percent were pandrug-resistant, while regional analyses across the Arabian Gulf have documented rising resistance to carbapenems, fluoroquinolones, and aztreonam. The new single-center data, drawn from a secondary care setting that is often underrepresented in national surveillance reports, reinforce the message that resistance epidemiology is highly heterogeneous across institutions and regions — and that local data are essential for choosing empirical therapy wisely.

Saudi Arabia has responded at the policy level with its National Action Plan for Antimicrobial Resistance (2022–2025), which aims to strengthen surveillance systems, stewardship, and infection prevention nationwide. Studies like this one are the ground truth against which such plans will be judged. The study’s inclusion of the DTR classification alongside MDR and XDR is particularly valuable, because DTR captures the loss of susceptibility to the principal first-line antipseudomonal agents — the drugs clinicians actually reach for first — and has been linked to worse outcomes in Gram-negative infections.

The overall picture is neither pure doom nor easy reassurance. More than two-thirds of isolates in 2024 were still multidrug-resistant, nearly double the 2018 level, and fluoroquinolone resistance has become almost universal. Yet the significant declines in XDR prevalence in 2024, and the recovery in carbapenem susceptibility, show that resistance is not a one-way ratchet: it responds, sometimes relatively quickly, to the ecological pressures a hospital applies. For a pathogen that the global burden studies place among the deadliest sources of antimicrobial-resistance-associated deaths, that dynamism is the most actionable finding of all — a reminder that surveillance is not a bureaucratic exercise but a live instrument for steering therapy, and that stewardship decisions made today will be visible in the resistance curves of tomorrow.

Subject of Research: Longitudinal trends in antimicrobial resistance phenotypes of Pseudomonas aeruginosa in a Saudi hospital, 2018–2024

Article Title: Longitudinal trends in antimicrobial resistance phenotypes in Pseudomonas aeruginosa: a seven-year study

Article References: Longitudinal trends in antimicrobial resistance phenotypes in Pseudomonas aeruginosa: a seven-year study. (n.d.). https://doi.org/10.3389/frabi.2026.1912287

Image Credits: AI Generated

DOI: 10.3389/frabi.2026.1912287

Keywords: antimicrobial resistance, Pseudomonas aeruginosa, multidrug-resistant, extensively drug-resistant, difficult-to-treat resistance, surveillance, antimicrobial stewardship, Saudi Arabia, healthcare-associated infections, carbapenems, fluoroquinolones, hospital epidemiology

Difficult-to-treat resistance is a recently formalized category, and its technical definition matters for understanding why these infections are so alarming. According to the criteria widely adopted from United States Centers for Disease Control and Prevention guidance and reflected in the Clinical and Laboratory Standards Institute’s M100 performance standards, a Gram-negative pathogen is labeled DTR when it is nonsusceptible to all agents in the standard first-line categories: all penicillins and beta-lactam and beta-lactamase inhibitor combinations, all cephalosporins, all carbapenems, the fluoroquinolones, and at least one of the aminoglycosides. In practical terms, a DTR Klebsiella isolate leaves clinicians with almost nothing from the traditional antibiotic armamentarium, forcing reliance on newer beta-lactam and beta-lactamase inhibitor combinations, tetracycline derivatives such as eravacycline, or the last-resort polymyxin colistin, each of which carries its own limitations in efficacy, toxicity, and availability.

The biology of Klebsiella pneumoniae makes it a particularly formidable opponent in cancer care. The organism is a Gram-negative bacillus equipped with an outer membrane rich in porins and a polysaccharide capsule that shields it from complement-mediated killing and phagocytosis. Resistance in DTR strains typically arises through the acquisition of beta-lactamase genes, including extended-spectrum beta-lactamases and carbapenemases such as those of the KPC, NDM, OXA-48-like, and VIM families, which hydrolyze the drugs that would otherwise destroy the cell wall. These genes frequently sit on plasmids that can transfer horizontally between bacterial species, meaning that resistance can spread within a hospital’s microbial ecosystem even when individual bacterial cells do not. For patients whose immune defenses are dismantled by chemotherapy, neutropenia, invasive devices, and repeated hospitalizations, such an organism finds an environment with few natural barriers.

Cancer patients represent a uniquely vulnerable population for these infections, a point the Varanasi team emphasizes by situating their investigation squarely in supportive care rather than pure microbiology. Intensive chemotherapy regimens produce prolonged periods of severe neutropenia, during which the body’s primary cellular defense against bacteria is largely absent. Mucosal barriers lining the gastrointestinal tract are damaged by cytotoxic drugs, allowing intestinal colonizing bacteria to translocate into the bloodstream. Central venous catheters, urinary catheters, and ventilatory support provide direct conduits for microorganisms to bypass skin defenses. Prolonged and repeated hospital admissions increase exposure to the hospital flora, and broad-spectrum prophylactic or empiric antibiotics, often necessary in this population, apply the selective pressure that favors resistant strains over susceptible competitors. The result is a patient population in which multidrug-resistant Gram-negative infections are both more common and more lethal than in the general hospitalized population.

Recent evidence underscores how grim the prognosis has become even in high-resource settings. A retrospective cohort study published in The Lancet Infectious Diseases in 2026 by Walker and colleagues examined survival trends among patients with difficult-to-treat, antibiotic-resistant Gram-negative infections in the United States during the era of next-generation antibiotics, and its inclusion in the Varanasi paper’s reference list signals the authors’ awareness that mortality in this syndrome remains substantial despite the arrival of new drugs. Severe infections caused by difficult-to-treat Gram-negative bacteria, as reviewed by Dettori, Bassetti, and colleagues in Current Opinion in Critical Care, frequently present as bloodstream infections, ventilator-associated pneumonia, or complicated intra-abdominal infections, and delays in appropriate empiric therapy are consistently associated with worse outcomes. In oncology patients, the combination of host immunosuppression and near-total antibiotic resistance creates a clinical scenario in which every hour of ineffective therapy matters.

Accurate susceptibility testing is therefore not a laboratory formality but a life-or-death variable, and this technical dimension occupies a significant place in the Varanasi group’s broader research program. Colistin, the polymyxin antibiotic often reserved for DTR organisms, is notoriously difficult to test reliably. Its large, amphipathic molecule aggregates in aqueous solution and does not diffuse well in agar, which is why traditional disk diffusion performs poorly. The reference standard, broth microdilution, is technically demanding and impractical for many laboratories in resource-limited settings. In response, the Clinical and Laboratory Standards Institute has endorsed broth disk elution as an alternative, a method in which colistin is eluted from a disk into broth before inoculation. A 2025 study by Chandankhede, Karyakarte, and colleagues compared broth disk elution with broth microdilution for carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, and a prospective study by CV, Priya, Chauhan, and Dhingra specifically evaluated the diagnostic performance of the two methods for carbapenem-resistant Gram-negative bacilli from cancer patients in India. These methodological comparisons matter because an erroneous report of susceptibility, or of resistance, directly changes whether a critically ill cancer patient receives an effective regimen.

The Varanasi investigation itself was structured as a formal healthcare-associated outbreak investigation, a discipline with well-established epidemiological methods. Outbreak investigation in a hospital setting begins with case ascertainment and the construction of a case definition, followed by descriptive epidemiology that maps cases by person, place, and time to identify patterns of transmission. When multiple patients harbor isolates with identical or closely related resistance profiles, the possibility of a common source or of clonal spread via healthcare workers’ hands, contaminated equipment, or the shared hospital environment must be systematically evaluated. The authors acknowledge support for the infection prevention and control assessment component of their investigation from Professor Purva Mathur of the Jai Prakash Narayan Apex Trauma Centre at AIIMS New Delhi and from Dr. A. S. Valan, a public health specialist at the Centers for Disease Control and Prevention India Country Office in New Delhi, indicating that the assessment was aligned with international standards, including the World Health Organization’s 2023 assessment tool on infection prevention and control minimum requirements for tertiary health care facilities.

That WHO tool provides a structured framework for evaluating whether a tertiary facility meets minimum IPC standards across core components such as governance and dedicated IPC staffing, guidelines and protocols, surveillance of healthcare-associated infections, microbiology laboratory capacity, environmental cleaning and sterilization, and the built environment and equipment. In cancer hospitals, the stakes of each component are amplified. High-touch surfaces around immunosuppressed patients, shared bathroom facilities, water systems, and medical devices all represent potential reservoirs for Klebsiella, which can survive on inanimate surfaces for extended periods. Hand hygiene compliance, cohorting of colonized or infected patients, rigorous terminal cleaning of rooms, and antimicrobial stewardship programs that limit unnecessary broad-spectrum exposure form the interlocking defenses that keep resistant organisms contained. An outbreak of DTR Klebsiella in such a setting is therefore as much a systems failure as a microbiological event, and the investigation’s value lies in identifying which links in the chain of transmission broke down.

The broader significance of the study extends well beyond a single institution in northern India. Carbapenem-resistant Klebsiella pneumoniae has been designated a critical-priority pathogen on the World Health Organization’s bacterial priority pathogens list, and the global spread of carbapenemase genes, particularly those encoding NDM-type enzymes that are endemic across the Indian subcontinent, means that cancer centers everywhere face converging threats. The Varanasi paper’s title phrase, beyond the tumor, captures a conceptual shift that supportive oncology has been undergoing: survival in cancer medicine increasingly depends not only on the effectiveness of antineoplastic therapy but on the invisible war being waged against resistant bacteria in the wards, laboratories, and plumbing of the hospitals where treatment occurs. As next-generation antibiotics arrive, their durability will depend on how well healthcare systems prevent the transmission events that this outbreak investigation documents, because every new drug deployed against a resistant cluster applies the selective pressure that can eventually render it ineffective too.

For clinicians and hospital administrators, the message of the study is operational as much as scientific. Rapid detection of DTR phenotypes through reliable susceptibility methods, prompt notification of infection control teams when clusters emerge, disciplined application of contact precautions, and sustained investment in laboratory capacity and IPC infrastructure are the concrete measures that determine whether a cluster remains a cluster or becomes a sustained institutional epidemic. For patients and families, the study is a reminder that modern cancer care is a team effort in which microbiologists, infection preventionists, and oncologists share responsibility for outcomes, and that the fight against antimicrobial resistance is inseparable from the fight against cancer itself.

Subject of Research: Healthcare-associated outbreak of difficult-to-treat Klebsiella pneumoniae infection among cancer patients

Article Title: Beyond the tumor: cluster of difficult-to-treat (DTR) Klebsiella pneumoniae infection in cancer patients—healthcare-associated outbreak investigations

Article References: Bajpai, V., Mishra, A., John, N., Sarode, R., Chaurasia, A., Bharti, S., Kapoor, A., & Mishra, B. K. (2026). Beyond the tumor: cluster of difficult-to-treat (DTR) Klebsiella pneumoniae infection in cancer patients—healthcare-associated outbreak investigations. Supportive Care in Cancer, 34(10), Article 1055. https://doi.org/10.1007/s00520-026-11277-7

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11277-7

Keywords: Klebsiella pneumoniae, difficult-to-treat resistance, antimicrobial resistance, cancer patients, healthcare-associated infection, outbreak investigation, infection prevention and control, carbapenem-resistant Enterobacterales, colistin susceptibility testing, supportive oncology, immunocompromised hosts, hospital epidemiology